SCHEMBL2371027

SCHEMBL2371027

CN(C)c1cc2c(=O)c3cc(Br)ccc3oc2cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
EGFR P00533 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
TBK1 Q9UHD2 1/20 0.41
PIM1 P11309 2/20 0.40
CSNK2A2 P19784 2/20 0.40
CSNK2B P67870 2/20 0.40
CSNK2A1 P68400 2/20 0.40
CDC7 O00311 1/20 0.40
PIM3 Q86V86 1/20 0.40
CSNK2A3 Q8NEV1 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
MAPT P10636 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL571197 0.78 KMT2A (0.44) KMT2AEGFRSMN1; SMN2KDM4ELMNA
SCHEMBL2588529 0.78 PIM1 (0.58) KMT2ASMN1; SMN2KDM4ELMNATBK1
SCHEMBL29416622 0.78 PIM1 (0.58) KMT2ASMN1; SMN2KDM4ELMNATBK1
SCHEMBL2371193 0.74 MAPT (0.38) KDM4EMAPTNPC1RAB9AALDH1A1
SCHEMBL28458382 0.74 KMT2A (0.55) KMT2ASMN1; SMN2KDM4ELMNATBK1
SCHEMBL30593476 0.74 KMT2A (0.55) KMT2ASMN1; SMN2KDM4ELMNATBK1
SCHEMBL19217398 0.72 CSNK2A2 (0.62) KMT2ASMN1; SMN2KDM4ELMNAPIM1
SCHEMBL47040 0.72 PIM1 (0.51) KMT2ASMN1; SMN2KDM4ELMNATBK1
SCHEMBL30593469 0.72 PIM1 (0.51) KMT2ASMN1; SMN2KDM4ELMNATBK1
SCHEMBL874481 0.72 KMT2A (0.56) KMT2ASMN1; SMN2KDM4ELMNATBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP KMT2A 3694/4885EGFR 2990/4885SMN1; SMN2 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.